Alicia Morgans, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Dendreon
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Clovis
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Genetech
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Sanofi
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Astellas
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Astra Zeneca
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Genetech
    Date added:
    Date updated:
    04/02/2024

Pages

Return to Advances in ADT: Part II: A Guide for Urologists (2023)